Table 3: HRME performance.
Reference |
Year |
Pathology |
Sensitivity |
Specificity |
Accuracy |
Vila, et al. [33] |
2014 |
Esophageal adenocarcinoma |
90% |
82% |
90% |
Lee, et al. [67] |
2014 |
Esophageal adenocarcinoma |
100% |
94.90% |
95% |
Protano, et al. [34] |
2015 |
Esophageal squamous cell carcinoma |
90% |
89% |
90% |
Shin, et al. [68] |
2015 |
Esophageal squamous cell carcinoma |
84-93% |
92-97% |
94% |
Parikh, et al. [71] |
2015 |
Colon cancer |
94% |
95% |
94% |
Varela, et al. [72] |
2013 |
Anal cancer |
90% |
88% |
|